Najjar Sonia M, Shively John E
Department of Biomedical Sciences and the Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
Department of Immunology and Theranostics, Arthur D. Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Eur J Clin Invest. 2024 Dec;54 Suppl 2(Suppl 2):e14338. doi: 10.1111/eci.14338.
This review focuses on a special aspect of hepatic lipid storage and inflammation that occurs during nutritional excess in obesity. Mounting evidence supports that prolonged excess fatty acid (FA) uptake in the liver is strongly associated with hepatic lipid storage and inflammation and that the two processes are closely linked by a homeostatic mechanism. There is also strong evidence that bacterial lipids may enter the gut by a common mechanism with lipid absorption and that there is a set point to determine when their uptake triggers an inflammatory response in the liver. In fact, the progression from high uptake of FAs in the liver resulting in Metabolic dysfunction-associated steatotic liver disease (MASLD) to the development of the more serious Metabolic dysfunction-associated steatohepatitis (MASH) depends on the degree of inflammation and its progression from an acute to a chronic state. Thus, MASLD/MASH implicates both excess fatty acids and progressive inflammation in the aetiology of liver disease. We start the discussion by introduction of CD36, a major player in FA and lipopolysaccharide (LPS) uptake in the duodenum, liver and adipose tissue. We will then introduce CEACAM1, a major player in the regulation of hepatic de novo lipogenesis and the inflammatory response in the liver, and its dual association with CD36 in enterocytes and hepatocytes. We conclude that CEACAM1 and CD36 together regulate lipid droplet formation and inflammation in the liver.
本综述聚焦于肥胖营养过剩期间肝脏脂质储存和炎症的一个特殊方面。越来越多的证据支持,肝脏中脂肪酸(FA)摄取时间延长与肝脏脂质储存和炎症密切相关,且这两个过程通过一种稳态机制紧密相连。也有强有力的证据表明,细菌脂质可能通过与脂质吸收相同的机制进入肠道,并且存在一个设定点来决定其摄取何时会触发肝脏的炎症反应。事实上,从肝脏中高摄取脂肪酸导致代谢功能障碍相关脂肪性肝病(MASLD)发展到更严重的代谢功能障碍相关脂肪性肝炎(MASH),取决于炎症程度及其从急性到慢性状态的进展。因此,MASLD/MASH在肝病病因中涉及过量脂肪酸和进行性炎症。我们首先介绍CD36,它是十二指肠、肝脏和脂肪组织中FA和脂多糖(LPS)摄取的主要参与者。然后我们将介绍CEACAM1,它是肝脏中从头脂肪生成调节和炎症反应的主要参与者,并阐述其在肠上皮细胞和肝细胞中与CD36的双重关联。我们得出结论,CEACAM1和CD36共同调节肝脏中脂滴的形成和炎症。